Proactive, a digital financial news organization, is hosting three intrepid companies on the fast track to growth at its latest North American virtual investor conference.
Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) (FRA:AGW), GreenBank Capital Inc (CSE:GBC) (OTCMKTS:GRNBF) and ProPhase Labs (NASDAQ:PRPH) will present at the virtual showcase event on February 16, 2021.
Hosted by Proactive’s Christine Corrado, the event kicks off at 1:00pm ET on Tuesday.
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets.
The company specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Most recently, Algernon Pharmaceuticals signed a deal with lab services firm Charles River Laboratories for pre-clinical research studies on the psychedelic compound DMT to treat stroke.
The company said it plans to be the first research entity globally to pursue DMT for stroke in humans and is targeting to begin a clinical trial as soon as possible this year. So, the company may look again at a drug, which was tested for one disease, but may be better used for another. It focuses on treatments for billion-dollar global disease markets.
The firm believes repurposed compounds have a much lower risk of failing in human trials on safety issues. It says over 90% of drugs fail before Phase II, while development costs have ballooned to nearly US$2.5 billion, with an average timeline of 15 years.
Algernon Pharmaceuticals is led by CEO Christopher Moreau, a seasoned business professional in the life sciences sector with a strong background in biotechnology research, business development and a deep expertise in the capital markets. Moreau was previously CEO and Director of a publicly-traded company focused on the research & development of screening tests for prostate cancer, skin cholesterol and type 2 diabetes.
GreenBank Capital is a next-generation merchant banking business with a flexible low-cost overhead structure designed to help the business grow exponentially.
The company's investment approach is to identify companies with the capacity for rapid growth with a strong management team that can be scaled and prepared for a public listing over a period of 6-24 months.
GreenBank's portfolio companies comprise equity investments in 11 smallcap businesses, including: 19% of Staminier Limited, a United Kingdom Merchant Banking firm; 59.5% of Kabaddi Games Inc, developers of a mobile application game based on the sport of Kabaddi; 52.5% of Blockchain Evolution Inc, owners of the world's first identification-based blockchain, and 21.4% of Ubique Minerals Limited, a zinc exploration company in Newfoundland.
The company reported recently that its portfolio company Staminier has exercised its option and has now completed the acquisition of P&H Motorcycles Ltd, the south of England's biggest distributor of high-performance motorcycles, including Ducati, Yamaha, Kawasaki, Suzuki, KTM, Scrambler and Honda.
GreenBank Capital is led by David Lonsdale, President and CEO of US private equity company The Lonsdale Group. Previously, he was President of Allegiance Capital Corporation, a private investment bank focusing on mergers and acquisitions.
ProPhase Labs is a diversified medical science and technology company with deep experience with OTC consumer healthcare products and dietary supplements.
The company is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the US.
ProPhase Labs announced recently that it has begun new saliva-based, viral RT-PCR multiplex-testing as a laboratory-developed test classification. Emergency use authorization applications have been filed and confirmed by the US Food and Drug Administration (FDA) for its two new testing methodologies.
The company said its testing integrates the Spectrum Solutions saliva self-collection system with a new, advanced multiplex qPCR platform for the simultaneous RNA detection of not only COVID-19 but also its viral mutations, as well as Influenza A, B, and more.
ProPhase Labs is led by CEO Ted Karkus, who has long focused his career on investing, management consulting and managing emerging growth companies. Karkus previously financed and advised biotech/vaccine company ID Biomedical when it was valued at about $25 million. Seven years later, the company was sold to GlaxoSmithKline PLC (LON:GSK) for more than $1.4 billion.
About the event:
- Ours is an audience of astute high net worth investors, fund managers, private client brokers and analysts
- We look beyond the numbers and meet the people creating the value for shareholders
- Each company has a presentation slot followed by Q&A, giving you the chance to discover the real story
- You can watch the event afterwards on our YouTube channel